CVS and Rite Aid have joined the slew of antitrust lawsuits against AndroGel maker AbbVie and its affiliates and are seeking triple damages against the company for allegedly delaying the availability of cheaper generic drugs through patent lawsuits.
The pharmacy chains, in a lawsuit filed last week, allege that AbbVie and its partners used “sham” patent litigation against Teva Pharmaceutical Industries and Perrigo to monopolize the topical testosterone replacement market.
If not for the lawsuits, the plaintiffs say they and other AndroGel buyers could have stocked generic versions of the testosterone therapy in June 2013 rather than in December 2014. The year-plus delay cost the pharmacies hundreds of millions of dollars, they argue in the filing in Pennsylvania federal court.
Full Content: FiercePharma
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
